These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 21821634)
1. Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? Curzen N; Sambu N Heart; 2011 Sep; 97(17):1433-40. PubMed ID: 21821634 [No Abstract] [Full Text] [Related]
2. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Smit JJ; van Werkum JW; ten Berg J; Slingerland R; Ottervanger JP; Heestermans T; Dill T; Hamm C; van 't Hof AW; Heart; 2010 Nov; 96(22):1815-20. PubMed ID: 20889993 [TBL] [Abstract][Full Text] [Related]
3. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903 [TBL] [Abstract][Full Text] [Related]
4. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Geisler T; Zürn C; Simonenko R; Rapin M; Kraibooj H; Kilias A; Bigalke B; Stellos K; Schwab M; May AE; Herdeg C; Gawaz M Eur Heart J; 2010 Jan; 31(1):59-66. PubMed ID: 19812059 [TBL] [Abstract][Full Text] [Related]
5. [Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction]. Kremneva LV; Shalaev SV Ter Arkh; 2008; 80(12):89-95. PubMed ID: 19227916 [No Abstract] [Full Text] [Related]
6. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization. Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS Platelets; 2010; 21(3):183-90. PubMed ID: 20201634 [TBL] [Abstract][Full Text] [Related]
7. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely. Chhatriwalla AK; Bhatt DL Circ Cardiovasc Interv; 2008 Dec; 1(3):217-25. PubMed ID: 20031681 [No Abstract] [Full Text] [Related]
8. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Sibbing D; von Beckerath N; Morath T; Stegherr J; Mehilli J; Sarafoff N; Braun S; Schulz S; Schömig A; Kastrati A Eur Heart J; 2010 May; 31(10):1205-11. PubMed ID: 20159881 [TBL] [Abstract][Full Text] [Related]
9. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease. Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. de Carvalho HC Rev Port Cardiol; 1999 Jun; 18(6):657-8. PubMed ID: 10422464 [No Abstract] [Full Text] [Related]
19. A comparison of the metabolism of clopidogrel and prasugrel. Laizure SC; Parker RB Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914 [TBL] [Abstract][Full Text] [Related]